

Department of Biomedical Engineering



Overview : We want to wake people with type 1 diabetes to prevent dead in bed syndrome caused by alarm fatigue leading to the lack of emergency glucagon administration that prevents death.

Dead in Bed

What is Dead in Bed? A phenomenon that occurs with the sudden unexplained death of a patient with type 1 diabetes

- Happens with about 7% of type one diabetes patients
- About 5.2% of all US adults reported having type 1 diabetes and using insulin to treat it [1]
- About 22% of all youth diagnosed with diabetes are diagnosed with type 1 [1]
- About 25% of patients on intensive insulin therapy have at least one episode of severe hypoglycemia every year [2]
- Dead in Bed Syndrome is estimated to be the cause of death for about 5% of all type 1 diabetes related deaths
 - Average age ranges between 18 31.5 years [3]





Our Team



Adam Peters Biomedical Engineering Team Lead oject manager harge of ensurin l deadlines are m nd responsible fo 3D printing of the device.

ontact Informatio etersan@uci.ed



ngelica Esteve Manzo Biomedical Engineering Designer lizes SolidWor and LabView to design and code the device.

Contact Information: stevesa@uci.ed



Siana Jimenez Biomedical Engineering Manufacture charge of over fabrication of device through physical and nechanical mear

Contact Information: cjimene@uci.edı



Leslie Rangel Biomedical Engineering Facilitator cilitates expansi of the device by oviding support [.] all areas of device development anc production.

ntact Informatio lgrangel@uci.edu



Rebeca Silva Biomedical Engineering Marketing Advisc ovide insights an commendation to comnpany's marketing initiatives.

Contact Information: ebecas2@uci.edu

FDA Pathway

Waking Dead in Bed Team: Adam Peters, Angélica Esteves-Manzo, Siana Jimenez, Leslie Rangel, Rebeca

Silva

Project Advisor: Elliot Botvinick

FDA And ISO

- **510K Premarket Notification**
- A premarket submission that does not
- require companies to provide proof of safety and effectiveness data from clinical
- trials but does evaluate the effectiveness
- and safety of the new device through
- comparison of legally marketed and
- patented devices currently in the market. - Current market devices
- 1. Dexcom G6
- 2. Medtronic Minimed 770G
- 3. Abbott Freestyle Libre
- Must be submitted 90 days in advance from desired market date

ISO Standards

- 1. ISO 14971: manufacturers will identify hazards, evaluate the risks associated with use of the device. Risk management applies to all stages of the product life cycle.
- 2. ISO 62366-1: also known as the human factors engineering standard, it provides guidance on analyzing, developing, and evaluating the usability of the device.
- 3.ISO 17664-2 & ISO 20417 : information is to be provided by the medical device manufacturer for the processing of non critical medical devices
- 4. ISO 13485: quality management of the device
- 5. ISO 15223-1 : manufacturer will specify the symbols used to express certain information they supply on their device and will be placed on packaging or device itself



The purpose of our project is to wake type 1 diabetics from their sleep before entering a hypoglycemic state that has the potential to cause coma and even death. This device would alternate through various auditory alarms, as well as an olfactory alarm, which would avoid causing alarm fatigue within the patients.





Step 3: Motor starts rotating and breaks the ammonia inhalant capsule. Step 4: Fan is activated, and sends the ammonia inhalant aroma to the user, which will wake them up.







Figure 2: Showing Rotation of Capsule Breaking Component

Timeline

Ξ	DETAILS Spring Quarter																			
			March				April					MAY				June				
	PROJECT Timeline	Enter the date of the first Monday of each month>	2	9	16	23	30	6	13	20	27		4	11	18	19	26	1	8	15
		-Prototyping																		
		-Testing																		
		-Revision and Prototpying																		
		-Final Presentation																		
		-New Venture competition																		